ID | 1114 |
Name of the vaccine | Vivotif |
Microbe | Bacteria |
Disease name | Typhoid |
Name of bacteria | Salmonella typhi |
Type of vaccine | Live attenuated |
Nucleic acid content | DNA |
Age | Over 6 years |
Description of the vaccine | Contains the attenuated strain Salmonella typhi Ty21a. |
Name of the manufacturer | Crucell Switzerland LTD |
Name of the manufacturing country | Switzerland |
Year of manufacture | 1989 |
Clinical Phase status | Approved |
Bacterial strain | Gram negative bacteria. |
Efficacy | In Alexandria, Egypt - 95% decrease in the incidence of typhoid fever. In Santiago, Chile - vaccine efficacy was 29% for the single dose schedule and 59% for the 2-dose schedule. |
Vaccine formulation | Capsule |
Dosage | Four doses of vaccine be taken at the alternate day interval. Re-immunization dose of 4 vaccine capsules taken on alternate days be given every 5 years. |
Mechanism of action | Humoral anti-S. typhi LPS antibody response. |
Route of administration | Oral |
Indications | Selective immunization recommended for travellers or people in close contact with the bacteria. |
Export | Distributed by - Crucell Vaccines Inc., USA |
Approval | US FDA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | Abdominal pain, nausea, headache, fever, diarrhoea, vomiting and skin rash. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/75988/download |
Other name | NA |
Additional Links | NA
|